Tuesday, 17 Nov 2026 Breaking: Spanish journalist Karlos Zurutuza highlights media blackout, risks to reporters covering Balochistan at Germany conference
BREAKING: Apple launches AI platform | Tesla earnings beat estimates | Nvidia stock surges | Bitcoin crosses major resistance
Business

Sudarshan Pharma Eyes Global Growth with Proposed 9.5% Stake in US-Based MedTherapy Biotechnology

Sudarshan Pharma Eyes Global Growth with Proposed 9.5% Stake in US-Based MedTherapy Biotechnology

PNN
Mumbai (Maharashtra) [India], September 7: Sudarshan Pharma Industries Limited is looking to accelerate its global expansion and diversify into advanced oncology with a proposed acquisition of a 9.50% equity stake in US-based MedTherapy Biotechnology Inc.
The strategic investment, approved by the company’s Board, is expected to mark Sudarshan Pharma’s entry into the emerging cell and gene therapy ecosystem, particularly the CAR-T therapy segment. The move could broaden the company’s existing pharmaceutical and specialty-chemical business into higher-technology and innovation-led healthcare opportunities.
US-India platform at the centre of strategy
MedTherapy Biotechnology is developing an integrated CAR-T cell therapy and contract development and manufacturing platform, with technology development capabilities in the US and manufacturing infrastructure in India.
For Sudarshan Pharma, the proposed association could combine MedTherapy’s biotechnology capabilities with the company’s commercial reach, pharmaceutical relationships, sourcing expertise and execution capabilities. According to the company, the partnership has the potential to create a US-India platform covering innovation, manufacturing, commercialisation and patient access.
“This proposed investment represents a bold and potentially transformative step in Sudarshan Pharma’s growth journey,” said Hemal Mehta, Chairman and Managing Director, Sudarshan Pharma Industries Limited, adding that the company is seeking to enter an innovative area of modern healthcare while establishing a stronger presence in the United States.
Multiple growth avenues
The proposed investment could provide Sudarshan Pharma with access to the US biotechnology market and participation in advanced oncology. The company has identified potential opportunities across specialised technology, customers, contracts and distribution, as well as development, manufacturing, licensing and commercialisation.
https://www.bseindia.com/xml-data/corpfiling/AttachLive/6a47a13c-6520-43c4-b371-9852bf1ddb50.pdf
A key strategic element is the possibility of combining **US-based innovation with cost-efficient Indian manufacturing, creating a platform that could potentially scale across international markets.
The proposed transaction could also change the profile of Sudarshan Pharma by adding exposure to innovation-led healthcare segments characterised by specialised capabilities, significant unmet medical needs and international market potential.
Promoters also propose investment
Alongside the company’s proposed 9.50% investment, promoters Hemal Mehta and Sachin Mehta have separately proposed acquiring 1.50% each in MedTherapy Biotechnology. This would take the combined proposed interest of the company and its two promoters to 12.50%.
The transaction is expected to involve cash consideration denominated in US dollars. However, the proposed acquisition remains subject to legal, financial, commercial and technical due diligence, definitive agreements, applicable approvals and compliance with overseas-investment regulations.
Sudarshan Pharma is targeting completion by March 31, 2027, subject to fulfilment of the applicable conditions.
A potential shift towards innovation-led healthcare
Sachin Mehta, Joint Managing Director of Sudarshan Pharma, said the investment could provide the company with a platform spanning technology, manufacturing, market access and commercialisation, with the potential to build a scalable global business and create sustainable shareholder value.
The proposed deal represents a strategic shift in the company’s long-term growth narrative. While Sudarshan Pharma currently operates across contract manufacturing, chemical sourcing, pharmaceutical products and healthcare solutions the proposed MedTherapy investment could give it exposure to advanced biotechnology and global oncology markets.
(ADVERTORIAL DISCLAIMER: The above press release has been provided by PNN. ANI will not be responsible in any way for the content of the same.)

Tags

Related News

Credent and Flabs Partner to Expand Home Sample Collection for Diagnostic Labs Across India
Business
Credent and Flabs Partner to Expand Home Sample Collection for Diagnostic Labs Across India

<p>PNN<br/>New Delhi [India], November 17: <a href="https://c3logistics.co.in/" rel="noopener" target="_blank">Credent C...

India’s inland waterbodies could create 1.8 crore jobs, add USD 40 billion to economy: Report
Business
India’s inland waterbodies could create 1.8 crore jobs, add USD 40 billion to economy: Report

<p>New Delhi [India], November 17 (ANI): India's village ponds, tanks, lakes and reservoirs have the potential to double...

Taapsee Pannu and Jannat Zubair Team Up with NIVEA Soft to Simplify Everyday Hydration for Gen Z
Business
Taapsee Pannu and Jannat Zubair Team Up with NIVEA Soft to Simplify Everyday Hydration for Gen Z

<p>BusinessWire India<br/>Mumbai (Maharashtra) [India], November 17: NIVEA, India’s most trusted skincare brand*, launch...

Arpan Launches 8th Edition of Child Safety Week with Vidya Balan, Building a Nationwide Movement Against Child Sexual Abuse
Business
Arpan Launches 8th Edition of Child Safety Week with Vidya Balan, Building a Nationwide Movement Against Child Sexual Abuse

<p>NewsVoir<br/>Mumbai (Maharashtra) [India], November 17: Arpan, a globally recognised non-profit organisation dedicate...

Veefin Solutions Limited Expands Its Enterprise Software Business With the AI Operating System and AI Employees; Launches veefin.ai
Business
Veefin Solutions Limited Expands Its Enterprise Software Business With the AI Operating System and AI Employees; Launches veefin.ai

<p>BusinessWire India<br/>Mumbai (Maharashtra) [India], November 17: Veefin Solutions Limited (“Veefin” or “the Company”...

Dairy companies margins likely to improve in H2FY27 as milk procurement inflation peaks: Report
Business
Dairy companies margins likely to improve in H2FY27 as milk procurement inflation peaks: Report

<p>New Delhi [India], November 17 (ANI): Profit margins of Indian dairy companies are expected to improve in the second...